Recombinant factor VIIa for rapid reversal of anticoagulant effect in patients with intracranial hemorrhage: the Israeli experience and review of the literature.
Da'as
Nael
N
Department of Hematology, Coagulation Unit, Hadassah University Hospital, Hebrew University-Hadassah Medical School, Jerusalem, Israel. daasn@surfree.net.il
Misgav
Mudi
M
Kalish
Yossef
Y
Varon
David
D
D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000009:adverse effects / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D005167:Factor VII / Q000627:therapeutic use*; D015942:Factor VIIa; D005260:Female; D006408:Hematoma, Subdural / Q000209:etiology; D006801:Humans; D020300:Intracranial Hemorrhages / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D007557:Israel; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use; D020521:Stroke / Q000209:etiology; D014812:Vitamin K / Q000627:therapeutic use
D000925:Anticoagulants; D011994:Recombinant Proteins; D014812:Vitamin K; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa